Eurofins CDMO Alphora Inc. (Canada) Announces Completion of New API Manufacturing Facility
10 July 2024 - 4:00AM
Business Wire
Eurofins CDMO Alphora Inc. is excited to announce an expansion
of its API capacity and capabilities with the completion of its new
API manufacturing facility at its site in Mississauga, Canada. The
new API facility adds 15,000 sq ft of GMP processing and
warehousing space which complements Eurofins CDMO Alphora’s
existing API and drug substance manufacturing capabilities.
The addition of 2 x 2000 L reactors expands existing GMP plant
capacity and supports API batches to the 125kg scale. The new plant
provides additional capacity for Phase I through to
commercialization programs to support a growing client base and
pipeline. The facility is designed to handle up to Safebridge Class
3 compounds and includes two Hastelloy filter dryers to facilitate
API isolation and drying. The reactor systems can support
temperatures from cryogenic (-800C) to 2000C, as well as
hydrogenations and biotage chromatography.
The API plant expansion positions Eurofins CDMO Alphora at the
forefront of small molecule development and supporting the
manufacturing of life-saving therapies. This capacity expansion
will allow Eurofins CDMO Alphora to support existing and
prospective partners to address expanding therapeutic indications
and meet the growing demand for emerging therapies at clinical and
commercial stages. With its 20-year history in developing and
manufacturing highly complex processes for a variety of APIs and
HPAPIs, as well as its integrated offerings in Solid-State R&D
and Oral Drug Product Formulation, Eurofins CDMO Alphora is a
well-stablished CDMO partner of choice.
To learn more, visit: https://www.eurofins.com/cdmo
About Eurofins CDMO Alphora Inc. Eurofins CDMO, part of
the international network of Eurofins laboratories, is a leading
global Contract Development and Manufacturing Organization that
provides clients with active pharmaceutical ingredients (“API’s”) /
drug substance and drug product development for small molecules,
biologics and phytocannabinoids. Its service offering encompasses
drug substance/API development, solid state research and
development, pre-formulation, formulation and development,
analytical development, Non-GMP & GMP manufacturing, upstream
development, downstream development & ADC Conjugation.
Operating with facilities in Europe, North America and India,
Eurofins CDMO is accredited through the FDA, EMA, ANSM, ANSES,
FAMHP, PMDA, and Health Canada.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With ca. 62,000 staff across a
network of more than 900 laboratories in over 1,000 companies in 62
countries, Eurofins offers a portfolio of over 200,000 analytical
methods.
Eurofins Scientific S.E. shares are listed on Euronext Paris
Stock Exchange.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240709530980/en/
Cheryl Young Senior Vice President, Business Operations Eurofins
CDMO Alphora Inc. Cheryl.Young@bpt.eurofinsca.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Sep 2024 to Oct 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Oct 2023 to Oct 2024